A share price of Apellis Pharmaceuticals Inc [APLS] is currently trading at $21.0, up 4.32%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The APLS shares have gain 6.44% over the last week, with a monthly amount drifted -29.48%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wells Fargo started tracking the stock with Overweight rating on October 15, 2025, and set its price target to $32. On September 26, 2025, downgrade downgraded it’s rating to Sell but maintained its price target of $18 on the stock. Raymond James downgraded its rating to an Outperform but stick to its price target of $52 on May 09, 2025. BofA Securities downgraded its rating to a Neutral but $23 remained the price target by the analyst firm on May 09, 2025. Cantor Fitzgerald started tracking with an Overweight rating for this stock on April 29, 2025, and assigned it a price target of $44. In a note dated December 17, 2024, Goldman downgraded a Neutral rating on this stock but restated the target price of $36.
Apellis Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $16.10 and $35.72. Currently, Wall Street analysts expect the stock to reach $31.33 within the next 12 months. Apellis Pharmaceuticals Inc [NASDAQ: APLS] shares were valued at $21.0 at the most recent close of the market. An investor can expect a potential return of 49.19% based on the average APLS price forecast.
Analyzing the APLS fundamentals
Trailing Twelve Months sales for Apellis Pharmaceuticals Inc [NASDAQ:APLS] were 1.02B which represents 132.98% growth. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at 0.08%, Pretax Profit Margin comes in at 0.05%, and Net Profit Margin reading is 0.04%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.19 and Total Capital is 0.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.28 points at the first support level, and at 19.55 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.43, and for the 2nd resistance point, it is at 21.86.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Apellis Pharmaceuticals Inc [NASDAQ:APLS] is 3.54. As well, the Quick Ratio is 3.10, while the Cash Ratio is 1.71. Considering the valuation of this stock, the price to sales ratio is 2.61, the price to book ratio is 6.62 and price to earnings (TTM) ratio is 70.73.
Transactions by insiders
Recent insider trading involved Watson David O., General Counsel, that happened on Nov 17 ’25 when 5000.0 shares were sold. Officer, Watson David O. completed a deal on Nov 17 ’25 to buy 5000.0 shares. Meanwhile, Chief Financial Officer Sullivan Timothy Eugene sold 10000.0 shares on Oct 21 ’25.
